According to Zhitong Finance App, Columbotai Bio-B (06990.HK) announced that the company, along with cisplatin and gemcitabine, has been approved for listing in China by China's National Drug Administration (NMPA), an innovative humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) for first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC).

Zhitongcaijing · 01/20 12:17
According to Zhitong Finance App, Columbotai Bio-B (06990.HK) announced that the company, along with cisplatin and gemcitabine, has been approved for listing in China by China's National Drug Administration (NMPA), an innovative humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1) for first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer (NPC).